Neuropathology — Specialty Profile

Exploratory, not prescriptive. This profile blends hard data (pay, match rates, burnout, demographics, each sourced and dated) with generalizations and synthesized opinion about culture and "who fits." It's here to help you get curious and go find out for yourself, not to tell you who to become. Numbers marked ⟳ verify change every year; check the linked source before you quote one. Last reviewed: 2026-08-04.

Also called: neuropath, NP, brain pathology. A 2-year ACGME-accredited fellowship entered after a pathology residency, or from neurology or neurosurgery with additional anatomic pathology training. Organ systems: brain, spinal cord, peripheral nerve, muscle, and eye.

Subspecialty fellowship of Pathology, also entered from Neurology and Neurosurgery.

The 30-second version

Neuropathology is the diagnosis of disease in the nervous system from tissue, and it is the pathology subspecialty that has been most thoroughly rebuilt by molecular biology in the last decade. Brain tumor classification used to be a question of what a tumor looked like under the microscope. It is now a question of what it looks like and what its genome says, and since the World Health Organization's 2021 revision, several central nervous system tumors cannot be diagnosed at all without molecular data. A neuropathologist reading a glioma is integrating morphology with IDH mutation status, 1p/19q codeletion, and increasingly whole-genome methylation profiling to produce a single integrated diagnosis that determines what the neuro-oncologist does next. The other half of the field is what most people picture: autopsy neuropathology, which is still how neurodegenerative disease is definitively diagnosed, and which is the evidentiary backbone of Alzheimer's, Parkinson's, ALS, and CTE research. Add muscle and nerve biopsy, epilepsy surgery specimens, and intraoperative consultation for neurosurgeons, and you have a small, intellectually dense, almost entirely academic specialty. The trade at the center of the field: probably the most intellectually rich diagnostic work in medicine, in the longest pathology fellowship, leading to the narrowest job market and the lower end of pathology pay.

Quick dashboard (details and sources below)


Training after med school	6 years (4 yr AP/CP pathology + 2 yr neuropathology fellowship); shorter AP-only routes exist
Total from college start	~14 years (4 undergrad + 4 med school + 4 residency + 2 fellowship)
Training chain	Med school (4) → Pathology (4) → 2 yr ACGME neuropathology fellowship → ABPath neuropathology certificate
Entry routes	Pathology (primary); also neurology or neurosurgery board certification plus at least 1 yr of anatomic pathology ⟳
Competitiveness	No published match rate. Small field, most programs taking one fellow, and pathology fellowship recruitment is mid-reform ⟳
Typical full-time pay	No survey publishes neuropathology. Fellows' job offers clustered at $200,001–$250,000 (ASCP, 2020) against general pathology at $394,000 (Medscape 2026) / $373,384 (Doximity 2025) ⟳
Pay vs. parent (general pathology)	Below, and materially so. Practice settings are limited and almost entirely academic ⟳
Lifestyle	Microscope-based, daytime, weekday, minimal call beyond intraoperative consultation ⟳
Burnout	No subspecialty figure; parent pathology is 28.3% against a 41.9% all-physician average (AMA 2025), third-lowest of the rows it names ⟳
% women	50.9% of neuropathology fellows (ACGME, AY2024-25); parent pathology 44% practicing, 54.7% of residents ⟳
DO / IMG accessibility	Gated behind pathology, among the most open fields (19.6% DO, 34.7% IMG of the 2026 entering class); the fellowship itself runs 3.6% DO and 47.3% IMG (ACGME, AY2024-25, 55 fellows) ⟳

What they actually do

Surgical neuropathology is the clinical core. Brain and spinal cord tumors arrive from the operating room, and the neuropathologist produces the diagnosis that determines the treatment. Since the 2021 WHO classification of central nervous system tumors, that diagnosis is integrated by design: morphology, immunohistochemistry, and molecular markers combine into a single classification, and for several entities the molecular result is definitional rather than supportive. IDH mutation status separates the diffuse gliomas, 1p/19q codeletion defines oligodendroglioma, H3 K27 alteration defines a distinct midline glioma, and DNA methylation profiling has become a reference standard for hard cases.

Intraoperative consultation is the acute end. A neurosurgeon with an open craniotomy needs to know whether the tissue in front of them is tumor, and whether it is the kind that changes the operation. The neuropathologist reads a smear preparation and a frozen section in minutes while the patient is on the table. This is the field's real-time work and its most stressful.

Autopsy neuropathology remains central here in a way it is not elsewhere in pathology. Definitive diagnosis of neurodegenerative disease still requires examination of the brain after death: the distribution of tau, amyloid, alpha-synuclein, and TDP-43 pathology is what confirms Alzheimer's disease, Lewy body disease, progressive supranuclear palsy, or frontotemporal degeneration. Neuropathologists staff the brain banks that make dementia research possible, which is why the field sits at the center of a research enterprise far larger than itself. The clinical counterpart on the living side is behavioral neurology.

Muscle and nerve pathology is its own discipline within the discipline: muscle biopsy for the myopathies and muscular dystrophies, nerve biopsy for vasculitis and amyloid, with specialized processing and interpretation that general pathology does not cover. On the neurology side, UCNS accredits a parallel subspecialty in clinical neuromuscular pathology.¹

Representative work: integrated diagnosis of central nervous system tumors combining histology, immunohistochemistry, and molecular data · intraoperative smear and frozen section for neurosurgery · brain cutting and autopsy neuropathology, including neurodegenerative disease staging · muscle and nerve biopsy interpretation · epilepsy surgery specimens, including focal cortical dysplasia and hippocampal sclerosis · ophthalmic pathology at some centers · forensic neuropathology, including traumatic brain injury · brain bank curation and research collaboration.²

A day in the life: microscope, molecular reports, and conference. The daily rhythm is previewing and signing out surgical cases, waiting on and integrating molecular results, and being interrupted for intraoperative consultations. Brain cutting sessions, where fixed brains are sectioned and examined, are a scheduled weekly or biweekly ritual in most departments and are also the field's principal teaching format. Tumor board attendance is expected, and the neuropathologist is often the person whose result the room is waiting for.

Academic neuropathologists carry substantial research and teaching loads, and a meaningful share hold laboratory appointments, because the specimens they steward are the raw material of neuroscience research.

On call: light and specific. There is no overnight service, but intraoperative consultation happens whenever neurosurgery operates, which includes evenings and weekends at busy centers.

The training path & time to completion

Medical school (4 yrs) → anatomic pathology training → 2-year ACGME-accredited neuropathology fellowship → ABPath subspecialty certification in neuropathology.¹³

The fellowship is two years, which makes it the longest of the common pathology fellowships. Most of the others, including dermatopathology, cytopathology, hematopathology, and transfusion medicine, run one.¹
Combined AP and neuropathology certification requires 24 months of ACGME-accredited anatomic pathology training and 24 months of ACGME-accredited neuropathology training.³ That is the arithmetic behind the total.
Entry is more open than most pathology subspecialties, and the alternate doors matter. A fellow must have completed at least two years of anatomic pathology in an ACGME-accredited pathology residency, or hold ABPath certification or eligibility. Alternatively, a physician certified in neurology or neurological surgery by an ABMS member board needs only one year of anatomic pathology to be eligible.³ So a neurologist or neurosurgeon can convert into this field, which very few pathology subspecialties permit.
Total from the start of college: about 14 years via the standard AP/CP route.

Recruitment is in the middle of a reform, and where it stands matters. Pathology fellowships have historically had no unified match, with recruitment drifting so early that residents commit before rotating through the subspecialties. The College of American Pathologists and the Association for Academic Pathology are pushing a match: hematopathology, molecular genetic pathology, forensic pathology, and bone and soft tissue pathology committed for the 2026–27 academic year, with others invited to the 2027 cycle placing fellows for 2028–29.⁴ Neuropathology is not among the four that have committed. 85% of residents say they prefer a later, unified timeline.⁵ ⟳

How competitive is it?

No match rate is published, because until the current reform there was no match to report one.

The field is small. Most neuropathology fellowships take one fellow, and the specialty's total workforce is a few hundred practicing subspecialists nationally, which is why so many departments have one or two.
The two-year commitment self-selects hard. A pathology resident choosing between a one-year fellowship in a field with a broad job market and a two-year fellowship in a field with a narrow one is making a decision most residents resolve toward the former.
The alternate doors are genuinely open. A neurologist or neurosurgeon can enter with one year of anatomic pathology, and programs do take them.³
Demand exists and is unusual in shape. Neuropathology positions are tied to institutions that do neurosurgery and neuroscience research, so the number of jobs is set by the number of academic neuroscience centers rather than by patient volume.

The honest read. Not competitive in the sense of being fought over. Competitive in the sense that the small number of strong programs are the ones worth training at, and the job market afterward is narrow enough that where you trained and who knows you matters more than in most of pathology.

Board: ABPath subspecialty certification in neuropathology, one of eleven ABPath subspecialty certificates.¹

Compensation — the robust version

No compensation survey publishes a neuropathology line. Medscape and Doximity both stop at "pathology," and MGMA's subspecialty tables are paywalled. But one real source exists, and it is the field's own society.

The parent anchor. Medscape's Physician Compensation Report 2026 puts the pathologist average at $394,000 (2025 earnings) and Doximity's 2025 Physician Compensation Report puts it at $373,384 (2024 earnings). Those are the two published surveys for the parent field.⁶ ⟳

The one neuropathology-specific figure anyone publishes is a starting salary, and it comes from ASCP. The American Society for Clinical Pathology surveys its fellows every year about the job market, and it reports the answers broken out by fellowship, neuropathology among them. In the 2020 report, the largest group of neuropathology fellows who had received an offer put its starting salary in the $200,001–$250,000 band, with the next largest group above $250,000 and a smaller group between $150,001 and $200,000. Roughly twenty neuropathology fellows answered, and the offers they described were overwhelmingly academic: in the same survey, most neuropathology fellows' offers came from academic institutions and most expected to be salaried employees rather than partners.⁷ ⟳

Two things bound how far that number travels. It is a first job out of fellowship, so it sits below what the same person earns a decade in, and it is six years old. What it does establish, from a source that holds its own data, is that neuropathology starts well below the parent field's average and starts in academia.

The mechanism is structural rather than a reflection of difficulty. Pathology income scales with specimen volume, and the highest-paying pathology practices are high-throughput private laboratories. Neuropathology has no equivalent: brain specimens are comparatively few, they take a long time to work up, and the diagnostic value added is intellectual rather than volumetric. The jobs are at academic medical centers with neurosurgery programs, and academic pathology pays what academic pathology pays. There is no private-laboratory version of this field to arbitrage into.

A second and less obvious factor is that a large share of the work is not billable in the ordinary way. Autopsy neuropathology, brain bank curation, and research collaboration are central to what the field contributes and generate little clinical revenue. A neuropathologist's institutional value is substantially in teaching, research infrastructure, and tumor board expertise, none of which shows up in a professional fee.

So the honest statement is that this is the pathology subspecialty with the widest gap between intellectual standing and compensation. It is regarded within pathology as among the most demanding and most interesting fields, and it is paid below the parent specialty for reasons that have nothing to do with either.

What a mid-career neuropathologist earns is genuinely unknown. No survey, no society report, and no public record answers it. The reasoning that gets closest: start from the parent field's published average, $373,384 to $394,000 depending on the survey, subtract the private-laboratory volume that lifts the rest of pathology and that this field has no access to, and land in the academic-pathology band at your institution. That is an inference from the job market rather than a measurement of it, and it is why the practical advice below matters more here than a number would.

Limited-data caveat: the only neuropathology-specific compensation figure on this page is a 2020 starting-salary band from ASCP's fellow survey. Everything else is the parent field or reasoning about setting. Benchmark against the academic pathology salary scale at the institution making you an offer, and ask people in the field directly, because there is no national number to check them against. ⟳

Lifestyle

Daytime, weekday, and controllable, inheriting the parent field's defining advantage. Pathology has little traditional call and neuropathology adds only intraoperative consultation.⁸
Intraoperative consultation is the one thing that pulls you in. Neurosurgery operates on evenings and weekends, and a frozen section cannot wait. At a busy center this is a real if intermittent obligation.
The pace is deliberate rather than frantic. Case volumes are lower than in high-throughput pathology because the specimens are complex and molecular results take time to return. That makes the work intellectually intense and temporally forgiving, which is an unusual combination.
Academic structure shapes the week, with tumor boards, brain cutting sessions, teaching, and research protected or expected depending on the appointment.
Geographic flexibility is poor. The jobs are at academic medical centers with neurosurgery and neuroscience programs, and there are not many. This is the field's most binding practical constraint.

Lifestyle rating: 4/5. Excellent hours and control, deducted for intraoperative call and, more seriously, for a job market that limits where you can live.

Wellbeing — the part to take seriously

No neuropathology-specific wellbeing data exists.

Burnout inherits pathology at 28.3% against a 41.9% all-physician average, third-lowest of the rows the AMA's 2025 Organizational Biopsy names.⁸ Controllable hours, no emergency exposure, and intellectual autonomy are the usual explanations, and all hold here. ⟳

The distinctive pressure is intraoperative. A surgeon is standing in an open cranium waiting for your answer, and the answer changes the operation. Getting a smear preparation right in minutes, on limited tissue, under time pressure, with a resection extent hanging on it, is a specific kind of stress that the rest of the field's deliberate pace does not prepare you for.

The emotional content is unusual. Neuropathologists diagnose diseases with poor outcomes, and they diagnose many of them after the patient has died. Glioblastoma is a large part of the surgical practice. Autopsy work means examining the brains of people whose families are waiting for an answer about what happened to them, and in the neurodegenerative context that answer often carries genetic implications for the children who requested it. Practitioners describe the autopsy conversation with families as among the most meaningful parts of the job, and it is not what outsiders assume pathology involves.

The intellectual satisfaction is the field's strongest retention factor, and it is not a small thing. Neuropathology has absorbed more genuinely new science in the last fifteen years than almost any diagnostic field, and practitioners consistently describe the work as the reason they stay despite what it pays.

The isolation risk is real. Many departments have one or two neuropathologists, so professional community is thin locally and depends on national societies and consultation networks. For a subspecialty this narrow, that is a structural feature rather than an accident of a particular job.

Who's in the field (demographics)

ACGME publishes neuropathology's sex and medical-school-type splits at fellow level. Nothing else neuropathology-specific is published, which is what happens in a field this size, so inherit pathology for race and ethnicity and treat that as directional.

Women: 50.9% of neuropathology fellows in AY2024-25, close to the 49.5% across all active residents and fellows. Parent pathology runs 44% women practicing (AAMC, 2022 data) and 54.7% of residents.⁸ ⟳
DO: parent pathology is among the most DO-accessible specialties, at 19.6% of the 2026 entering class, and the fellowship narrows sharply from there. Of the 55 neuropathology fellows ACGME counted in AY2024-25, 2 were osteopathic graduates, or 3.6%, against 13.9% across all pathology residents. Two fellows out of 55 makes the point estimate fragile, and the direction is what carries.⁸ ⟳
IMG: parent pathology runs 34.7% IMG of its entering class, among the highest of any specialty, and the fellowship widens further rather than narrowing: 26 of those 55 fellows trained at an international medical school, or 47.3%. That makes this one of the more internationally accessible routes into a highly specialized academic career.⁸ ⟳
Underrepresented in medicine: no subspecialty figure. Pathology's overall profile is inherited. ⟳
A note on the alternate doors. Because neurologists and neurosurgeons can enter with one year of anatomic pathology, the fellowship cohort is not demographically homogeneous with pathology residents, and neurosurgery in particular is a far less DO- and IMG-accessible parent.³ ⟳

Culture, personality & the online stereotypes

Who gravitates here: people for whom the nervous system was the interesting part of medicine and the microscope was the interesting tool. The field draws heavily from residents with research backgrounds, and a substantial share hold PhDs or run laboratories, because neuropathology sits directly on top of neuroscience research infrastructure. It rewards patience, comfort with complexity, and willingness to be the person in the department who knows one thing very deeply. As always, plenty of people in the field do not fit any single mold.

The stereotypes. Community perception rather than fact, each with a kernel and an unfair edge:

"The brain cutters." The autopsy caricature. Autopsy neuropathology is genuinely central here in a way it no longer is elsewhere in pathology, and it is also a minority of the work at most centers, where surgical tumor diagnosis dominates.
"The smartest and worst-paid people in pathology." Said with real affection inside the specialty, and the compensation half is supported by the only figure anyone publishes.⁷
"A two-year fellowship for a job that might not exist where you want to live." The honest warning residents give each other, and the most practical thing on this page.
"Molecular ate the field." An overstatement of something true. Molecular data became definitional for CNS tumor classification, and morphology remains the framework the molecular results are integrated into. The neuropathologists who thrived are the ones who absorbed the genomics rather than resisted it.

What people say online (synthesized and paraphrased, not quotes): across trainee and physician forums, neuropathology reads as the connoisseur's subspecialty. The recurring admiring theme is intellectual depth, with posters describing it as the most interesting thing in pathology and the field where the science has moved fastest. The recurring warning is the job market, with repeated advice that neuropathology positions are academic, few, and geographically fixed, and that a resident should not enter the fellowship without a realistic view of where they might end up. A third thread is the two-year length, discussed as a substantial opportunity cost against one-year fellowships with broader employability. A fourth, more recent, concerns methylation profiling and whether reference-laboratory molecular classification will eventually do more of the diagnostic work than the neuropathologist does. The tone is unusually respectful and unusually candid about the economics.

Voices from the field. Paraphrased from published sources, with links to the originals:

ABPath lists neuropathology among its eleven subspecialty certifications, and combined AP and neuropathology certification requires 24 months of ACGME-accredited anatomic pathology training plus 24 months of ACGME-accredited neuropathology training.¹³
Entry requirements are broader than most pathology subspecialties: at least two years of anatomic pathology in an ACGME-accredited residency or ABPath certification, or, for physicians certified in neurology or neurological surgery by an ABMS member board, at least one year of anatomic pathology.³
The College of American Pathologists and the Association for Academic Pathology are moving pathology fellowship recruitment toward a unified match, with four subspecialties committed for 2026–27 and 85% of residents preferring a later unified timeline; neuropathology has not yet committed.⁴⁵

Why people choose it / why people leave

Why choose it: probably the most intellectually rich diagnostic work in medicine, and the diagnostic field most transformed by molecular biology in the last fifteen years · a central role in tumor boards and in neuroscience research, well beyond what the specialty's size suggests · autopsy neuropathology as the definitive answer in neurodegenerative disease, and the brain banks that make dementia research possible · excellent hours and control, with no overnight service · alternate entry doors from neurology and neurosurgery · genuine expertise scarcity, since most departments have one or two of you.

Why leave or avoid it: the longest pathology fellowship at two years · pay materially below general pathology, with no private-laboratory route to arbitrage · a narrow, academic, geographically fixed job market · professional isolation in small departments · intraoperative consultation pressure · a large share of unbillable work in autopsy, research, and teaching.

Best fit if: the nervous system is what you find most interesting and the microscope is how you want to approach it · you want an academic career with research adjacency · you can accept a narrow geographic map · you are comfortable being the only person in the building who does what you do · the intellectual return matters more to you than the financial one.

Not for you if: you want pathology's income ceiling, which is in high-volume private laboratory work · two years of fellowship is more than you can afford · you need geographic freedom · professional isolation would wear on you · you want a broad job market you can move around in.

The FLI angle — Neuropathology for first-gen, low-income & immigrant students

Where it fits FLI realities well:

The front door is genuinely open, and that is rare for a field this specialized. Pathology runs 19.6% DO and 34.7% IMG of its entering class, among the most accessible specialties in medicine.⁸ A career at the center of academic neuroscience is reachable through one of the least gatekept residency matches there is, which is not true of most intellectually elite destinations. The second door is narrower, and it narrows in opposite directions for the two groups: neuropathology fellows are 3.6% osteopathic and 47.3% international, so relative to the match that feeds it the fellowship widens for an international graduate and closes for an osteopathic one. Two DO fellows out of 55 is a fragile point estimate, and the direction is the part to plan around.⁸ ⟳
PSLF fits this path better than almost any other pathology subspecialty, precisely because the jobs are academic. Academic medical centers are qualifying employers, four residency years and two fellowship years count toward the 120 payments, and the field has essentially no private-employer alternative. Where PSLF and pay pull in opposite directions in dermatopathology, here they point the same way.
The lifestyle is sustainable, with daytime hours and no overnight service.
Scarcity is leverage of a kind. A department that needs a neuropathologist has few candidates, and that is a different negotiating position from a field with a surplus.

Risks to name honestly:

This is the largest pay-versus-training-length trade on the pathology side of the Sky, and it needs arithmetic. Two fellowship years at trainee income, arriving at a subspecialty whose one published figure, a starting salary, sits well below the parent field's average, in a specialty already paid below most of medicine.⁶⁷ If your family's financial position depends on your income, model that against a one-year fellowship in dermatopathology or hematopathology before committing. It may still be the right choice; it should not be an accidental one.
The job market is narrow and academic, which constrains geography hard. If living near family in a specific place is non-negotiable, this field probably cannot accommodate it. That is a heavier cost for students with family obligations than the salary difference is.
Academic careers reward capital you may not have. Research output and mentorship decide the strong positions, and protected research time is easier to accept when nobody depends on your salary.
The compensation data is poor, so you will be negotiating without a reliable benchmark. Ask people in the field directly, and ask about academic salary scales rather than national averages.

Bottom line for FLI: a field of unusual intellectual depth with an unusually open entrance, attached to a long fellowship, a narrow map, and pay below its own parent specialty. The PSLF fit is genuinely strong and does real work against that. If the nervous system is what draws you and you can be flexible about geography, pathology is one of the few residencies that will let you in the door, and this is one of the most interesting places that door leads.

Fun facts

Since the 2021 WHO classification, several central nervous system tumors cannot be diagnosed on morphology alone. The molecular result is part of the definition rather than a confirmation of it.
Neurodegenerative disease is still definitively diagnosed after death. Alzheimer's, Lewy body disease, PSP, and FTD are confirmed by the distribution of protein pathology in the brain, which is why neuropathologists staff the brain banks that dementia research depends on.
It is the longest of the common pathology fellowships at two years, where dermatopathology, cytopathology, hematopathology, and transfusion medicine each run one.¹
A neurologist or neurosurgeon can convert into it with a single year of anatomic pathology, which almost no other pathology subspecialty allows.³
Brain cutting is a scheduled departmental ritual, not a metaphor. Fixed brains are sectioned and examined in a session that doubles as the field's principal teaching format.
It has the widest gap in pathology between how the subspecialty is regarded and what it pays, and the reason is specimen volume rather than difficulty.

Sources

Fellowship length, accreditation, and the ABPath subspecialty list. Duke University Department of Pathology — Fellowship Programs (neuropathology listed as a 2-year ACGME-accredited fellowship, against 1-year ACGME fellowships in cytopathology and dermatopathology): https://pathology.duke.edu/education/fellowships. American Board of Pathology — Subspecialty Certification, listing eleven subspecialty certificates including neuropathology, and noting that candidates may qualify after one or two years of ACGME-accredited fellowship training: https://abpath.org/subspecialty-certification/. UCNS accredits a parallel clinical neuromuscular pathology subspecialty on the neurology side: https://www.aan.com/news/nine-programs-ucns-accreditation-application-deadline (all accessed 2026). ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶
Clinical scope of neuropathology practice — surgical neuropathology and integrated CNS tumor diagnosis, intraoperative smear and frozen section, autopsy neuropathology and neurodegenerative disease staging, muscle and nerve biopsy, epilepsy surgery specimens, and brain bank work. Composite of published US neuropathology fellowship curricula: UCSF Neuropathology Fellowship (https://pathology.ucsf.edu/training/fellowship/ap/neuropath), UPMC Neuropathology Fellowship (https://www.neuro.pathology.pitt.edu/overview-upmc-neuropathology-fellowship-training-how-apply), and Keck USC Neuropathology Fellowship (https://keck.usc.edu/pathology/training-education/fellowships/neuropathology-fellowship), accessed 2026. ↩
Training duration and entry routes. Neuropathology fellowship programs are two-year training programs; applicants for combined AP/NP certification must complete 24 months of ACGME-accredited anatomic pathology training and 24 months of ACGME-accredited neuropathology training. Prior to appointment, fellows must have completed at least two years of anatomic pathology in an ACGME-accredited pathology residency or hold ABPath certification or eligibility; applicants certified in neurology or neurological surgery by an ABMS member board must have completed at least one year of anatomic pathology in an ACGME-accredited pathology program. American Board of Pathology, Requirements for Certification (https://abpath.org/requirements/) and program eligibility statements per ². ⟳ ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸
Fellowship match reform. College of American Pathologists — "CAP Supports Fellowship Match Effort, Reinforces Workforce Commitment": CAP signed a joint statement proposed by the Association for Academic Pathology Fellowship Directors Committee; hematopathology, molecular genetic pathology, forensic pathology, and bone and soft tissue pathology committed to a match for the 2026–27 academic year, with other eligible subspecialties encouraged to join the 2027 cycle placing fellows for 2028–29. https://newsroom.cap.org/latest-news/cap-supports-fellowship-match-effort--reinforces-workforce-commitment/s/97304fd5-c16c-459d-a2ce-acb517b0bd06 ⟳ ↩ ↩²
The recruitment-timing problem. The Pathologist, "Fixing Fellowship Fatigue" (October 2025) — the pathology fellowship application and selection process has shifted earlier in residency, often requiring residents to commit before experiencing many subspecialty areas; 85% of residents prefer a later, unified timeline. https://thepathologist.com/issues/2025/articles/october/fixing-fellowship-fatigue/ ⟳ ↩ ↩²
The two published surveys for the parent field, neither of which breaks out a pathology subspecialty. Medscape Physician Compensation Report 2026 — pathology $394,000 on 2025 earnings; the primary is paywalled and returns HTTP 402. Doximity 2025 Physician Compensation Report (2024 earnings, ~37,000 US physicians) — pathology $373,384, openable directly at https://www.doximity.com/reports/physician-compensation-report/2025 . Both publish means rather than medians and neither is inflation-adjusted. Corrected 2026-08-13: this page previously gave neuropathology a $175,000–$288,000 range, alongside sibling-subspecialty ranges for dermatopathology and hematopathology, sourced to a compensation analysis compiling Salary.com, Glassdoor and BLS figures. Job-posting and job-board aggregators are excluded as compensation sources on this site, and an excluded aggregator's number is not evidence of anything, so the range is deleted rather than downgraded. The parent-field percentile ladder that stood alongside it (25th ~$320,000, median ~$390,000, 75th ~$450,000, partners $500,000–$550,000+) traces to a crowd-sourced salary panel and is also removed. ⟳ On Salary.com: its CompAnalyst benchmark is HR-reported employer survey data blended with job-posting data, not a physician panel. It is base-weighted and so runs low against total-compensation surveys, and it is used here for percentile structure rather than for levels. ↩ ↩²
The one neuropathology-specific compensation source, and it is a society survey of fellows. American Society for Clinical Pathology, 2020 Fellowship & Job Market Surveys — a report on the 2020 RISE, FISE, FISHE, NPISE, PISE and TMISE surveys, which break every result out by fellowship, neuropathology (NP) among them. Of neuropathology fellows who received a job offer, the largest group reported a starting salary of $200,001–$250,000, the next largest above $250,000, and a smaller group $150,001–$200,000; roughly twenty NP fellows answered the question, and the report's own summary across all five fellowship types is that "most job offers included a proposed starting salary between $150,000 and $250,000." The same report shows NP fellows' offers concentrated in academic institutions and NP fellows overwhelmingly expecting salaried-employee rather than partner-track status. https://ascpcdn.s3.amazonaws.com/static/Membership/pdf/2020+ASCP+Fellowship+and+Job+Market+Surveys.pdf . Two limits worth holding: these are offers to physicians finishing fellowship, so they are starting salaries and sit below mid-career pay, and the report is from 2020. The per-band fellow counts are published as a bar chart rather than as a table, so the ordering above is read off the chart and the exact counts are not quoted. ⟳ ↩ ↩² ↩³
Parent-field figures for pathology. The daytime/weekday schedule with little traditional call is carried from the pathology profile on this site, which is a cross-reference rather than a source. Corrected 2026-08-13: a parent-field compensation ladder was also carried here from that profile, where it traces to a crowd-sourced salary panel this site excludes; the two published pathology survey figures in ⁶ replace it. Burnout: AMA Organizational Biopsy 2025 — nearly 19,000 physician responses across 106 health systems in 38 states — puts Pathology at 28.3% against a 41.9% all-physician average, third-lowest of the rows it names, https://www.ama-assn.org/practice-management/physician-health/these-9-physician-specialties-report-highest-burnout-rates. Corrected 2026-08-17: the dashboard and the wellbeing section now lead with the AMA row rather than Medscape's ~41%. AMA is the instrument this page prefers wherever it publishes a row, because it is free, primary and current, and pathology is one of the roughly fifteen the Organizational Biopsy breaks out. The two baselines are seven points apart and never share a sentence. The Medscape reading, no longer the page's anchor: 41% against a 49% all-physician average — Physician Burnout & Depression Report 2024 (n=9,226, fielded July–October 2023), paywalled and returning HTTP 402. Corrected 2026-08-17: this footnote described the relays as agreeing on every row and named two. Only Healthgrades Pro (https://resources.healthgrades.com/pro/the-most-and-least-burned-out-physicians-by-specialty) prints a pathology row; Advisory Board (https://www.advisory.com/daily-briefing/2024/01/31/physician-burnout) prints six specialties and the 49% baseline, and pathology is not among them. Women practicing, 44%: AAMC, "Women are changing the face of medicine in America" (2022 data), https://www.aamc.org/news/women-are-changing-face-medicine-america. The 38.7% that used to sit here is AAMC's figure for physicians of every specialty combined (2024 data, AAMC 2025 Key Findings, https://www.aamc.org/data-reports/data/2025-key-findings), and it understates pathology by six points. Women in training, pathology (AP/CP) residents 54.7% and neuropathology fellows 50.9% in academic year 2024-25, against 49.5% across all active residents and fellows: ACGME, Data Resource Book, Academic Year 2024-2025, Table C.21, https://www.acgme.org/globalassets/pfassets/publicationsbooks/2024-2025_acgme_databook_document.pdf. Correction 2026-08-13: this page previously said no neuropathology-specific figure existed and carried the parent field at ~38% practicing with residents "roughly half," in the Quick dashboard and in Who's in the field. A fellowship figure exists, the practicing figure was the all-physician one, and "roughly half" was a little low. DO and IMG access to the parent match: NRMP, Results and Data: 2026 Main Residency Match, May 2026, Table 2, https://www.nrmp.org/wp-content/uploads/2026/05/Main_Match_Results_and_Data-2026.pdf, gives pathology 636 positions offered and 634 filled (99.7%), of which 124 went to osteopathic graduates (19.6%) and 220 to international graduates (34.7%). Both shares are computed on positions filled. Medical school type at fellow level: ACGME, Data Resource Book, Academic Year 2024-2025, Table C.15, the same volume as Table C.21 above, gives neuropathology 55 fellows — 27 from US LCME-accredited schools (49.1%), 26 international (47.3%), 2 osteopathic (3.6%) — against a parent pathology resident population of 42.2%, 43.9% and 13.9%. Corrected 2026-08-17: the body carried ~17% DO and ~36% IMG in four places, including the dashboard row and the FLI section's lead bullet, while this footnote already recorded them as superseded. The DO correction runs upward, so the body's argument got stronger rather than weaker. The body also said no additional fellowship filter on DO or IMG access was documented; Table C.15 documents one in both directions, one table away from the Table C.21 cited above. And the 19.6% and 34.7% were described here as shares "of the 636 positions offered" when they are computed on the 634 filled; on the offered denominator they are 19.5% and 34.6%. ⟳ ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

Researched with AI assistance and reviewed by hand. How this site is made